Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic (MDT) demonstrates weak fiscal fourth-quarter performances at CER, attributable to dismal show in all major business segments and geographies.

Medtronic (MDT) Q4 Earnings Miss Estimates, Revenues Beat

Medtronic PLC (MDT) CEO Geoff Martha on Q4 2020 Results - Earnings Call Transcript

The medical device giant's Q4 revenue and earnings fell well short of expectations. Here's why.

What's Behind Medtronic's Q4 Earnings Miss

Medtronic (MDT) delivered earnings and revenue surprises of -1.69% and 1.20%, respectively, for the quarter ended April 2020. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Misses Q4 Earnings Estimates

Medtronic earnings and revenue missed fiscal Q4 views for the medical technology giant. MDT stock fell early Thursday.

Medtronic Earnings, Sales Fall Short; Medtech Giant Falls

Medical device company Medtronic Plc MDT, +1.08% said Thursday it had net income of $646 million, or 48 cents a share, in its fiscal fourth quarter to April 24, down from $1.172 billion, or 87 cents a share, in the year-earlier period.

Medtronic earnings fall short of estimates, but company raises quarterly dividend

DUBLIN, May  21, 2020  (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2020, which ended April 24, 2020. The results were in-line with the  update the company provided  on April 21, 2020, which detailed the impact of the COVID-19 pandemic on its operations and financials. Medtronic’s results were also consistent with the impact felt across the MedTech industry from deferred procedures as a result of the pandemic. Medtronic is in a strong financial position, as represented by the increase in its cash dividend announced today, and the company continues to drive its long-term strategies.

Medtronic Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Announces Dividend Increase

Medtronic's (MDT) new cannula will complement its entire portfolio of balloon kyphoplasty products, including Kyphon Xpander II Inflatable Bone Tamps.

Medtronic Launches Kyphon Cannula for Balloon Kyphoplasty

DUBLIN, May  19, 2020  (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. launch of  Kyphon Assist™ Directional Cannula  for use with its balloon kyphoplasty (BKP) products to treat vertebral compression fractures due to osteoporosis, cancer or benign lesions. This innovative new device allows physicians greater control when inflating the bone tamp while also increasing height restoration capability compared to a traditional balloon kyphoplasty cannula1.

New Directional Cannula Provides More Flexibility and Control to Balloon Kyphoplasty Procedures

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced Jeffrey J. Popma, M.D., professor of medicine at Harvard Medical School and director of interventional cardiology at Beth Israel Deaconess Medical Center in Boston, will join Medtronic as Vice President and Chief Medical Officer (CMO) supporting the Coronary, Renal Denervation, and Structural Heart businesses at Medtronic.

Jeffrey J. Popma, M.D. to Join Medtronic as Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart Businesses

Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.

Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?

Milestone Results Presented as Late-Breaking Clinical Science at SCAI 2020

Medtronic Congenital Heart Disease Studies Show Strong 10-Year Performance for Melody Transcatheter Pulmonary Valve and Primary Results from the Harmony Pivotal Trial

Medtronic (NYSE: MDT) shares were trading lower on Thursday, after DZ Bank downgraded the stock from Buy to Hold.

Why Medtronic's Stock Is Trading Lower Today

Johnson & Johnson

The healthcare sector is a safe space for investors looking for outstanding returns in difficult times.

Coronavirus Chaos Makes These 2 Healthcare Dividend Aristocrats Look Good

FDA Approves New ICDs and CRT-Ds with Advanced Remote Capabilities 

New Data Unveiled at Heart Rhythm 2020 Demonstrate Effectiveness of App-Based Remote Monitoring of Medtronic Cardiac Devices, Significant Reduction in Complications with Micra Leadless Pacemaker

Allstate

Bank of America

Diageo

Fortune Brands Home & Security

International Flavors & Fragrances

Lamb Weston Hlds

McCormick

NextEra Energy

Republic Services

Buy-and-hold stocks are key to a long-lasting, fruitful retirement. These 10 stocks to hold forever provide lasting income and safety.

10 Buy-and-Hold Stocks to Own Forever

Medtronic Assurance Program Will Provide Access to Glucose Sensors and Insulin Pump Supplies at No Cost to Eligible U.S. Customers

Medtronic Expands Diabetes Support Programs to Help Customers Losing Insurance Coverage Due to Job Loss as a Result of COVID-19

For PPL Corporation, May has been the strongest month for the share price in any year since 1980.

Stocks This Week: Buy PPL And Medtronic

Sensors, Infusion Sets and Reservoirs Donated to Organization Will Support Continuity of Therapy for People with Diabetes on Pump Therapy Experiencing Financial Hardships Due to COVID-19

Medtronic Gives $1 Million in Product Donations to Insulin for Life to Support COVID-19 Relief Efforts

“It strengthens our workplace culture . . . and ultimately helps us meet global healthcare needs.”

Medtronic’s Leadership Amidst Pandemic Proves The Power Of Innovation And Inclusion

General Electric

A Cold War-era law is being used to encourage manufacturers to produce and distribute critical supplies to healthcare workers.

Here's Why Trump Invoking The Defense Production Act Could Help Medtronic, GE, and Other Ventilator Makers

"Hospitals want to assure patients that if they have an issue, dial 911 and get to the hospital," Medtronic Executive Chairman Omar Ishrak told CNBC.

Medtronic chairman: Fear of hospitals may be behind increase in non-coronavirus deaths

The pandemic has sharply reduced the number of medical procedures being performed that use the company's medical devices.

Medtronic Reports Significant COVID-19 Impact on Its Business

TORONTO, April  23, 2020  (GLOBE NEWSWIRE) -- Celestica Inc. (NYSE, TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, today announced it is collaborating with Medtronic, one of the world's largest medical technology, services and solutions companies, to produce subassemblies for Medtronic Puritan Bennett™ 980 (PB980) ventilators.

Celestica Manufactures Ventilator Components for Medtronic in Response to the COVID-19 Pandemic

Medtronic stock declined 12% from $115 levels in the beginning of this year to $101 levels on April 20, compared to a 13% decline for the broader S&P 500. While Medtronic’s stock has performed in line with the broader markets, we believe there is only a limited upside from the current levels.

News for Medtronic Stock (MDT)